Abbott reported results from the U.K. FreeDM2 randomized controlled trial comparing FreeStyle Libre continuous glucose monitoring with fingerstick self-monitoring in 303 adults with type 2 diabetes using basal insulin across 24 clinical sites. The findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). At four months, the Libre group had a 0.6% greater reduction in HbA1c than the fingerstick group. The Libre group also spent about 2.5 more hours per day in the 70–180 mg/dL glucose range. Abbott also cited an Italian interventional study of 88 adults using Libre in routine practice that reported improvements after three months and was also being presented at ATTD.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603120300PR_NEWS_EURO_ND__EN08489) on March 12, 2026, and is solely responsible for the information contained therein.
Comments